# Pall Corporation chosen as single-source supplier for Servier's biomanufacturing facility in Gidy

Pall Corporation was selected by Servier as the exclusive technology and services provider for Servier's new biomanufacturing facility in Gidy, France. Pall will provide end-to-end biomanufacturing solutions for monoclonal antibodies and recombinant proteins. The Bio-S project includes up to 2,000L bioreactor capacity, with the Bio-engineering unit operational by 2019 and the rest by 2020.

- Type: Contract
- Announced: 2019-07-16
- Where: Gidy, France, France
- Status: announced
- Capacity: 2,000L bioreactor capacity
- Products: biomanufacturing solutions, monoclonal antibodies, recombinant proteins
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Pall Corporation](https://endata.com/companies/11324.md) (supplier)
- [Servier](https://endata.com/companies/40680.md) (customer)

## Sources

- [biospace.com](https://www.biospace.com/pall-corporation-chosen-as-single-source-supplier-by-servier-for-purpose-built-end-to-end-biomanufacturing-facility-in-gidy-france), 2019-07-16: "Pall was chosen as a single vendor for our unique ability to offer integrated solutions that help to guarantee supply chain security for customers and patients."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.